Study maps how tirzepatide binds its two target receptors

Researchers have published high-resolution images of tirzepatide locked onto both of the receptors it targets, showing how the drug mimics the natural hormone GIP at one receptor while engaging the other in a way that produces less receptor desensitization. The work appeared in the Proceedings of the National Academy of Sciences ^[1].

The team used cryogenic electron microscopy to determine three structures: the GIP receptor bound to native GIP at 3.2-angstrom resolution, the GIP receptor bound to tirzepatide at 3.1 angstroms, and the GLP-1 receptor bound to tirzepatide at 2.9 angstroms ^[1]. Angstroms are a measure of atomic-scale distance; lower numbers mean finer detail. Residues 1 through 32 of both GIP and tirzepatide were resolved in the maps ^[1]. The GLP-1 receptor structure has also been deposited in the Protein Data Bank under the accession code 7RGP ^[2]. In both receptors, tirzepatide folds into a helix with its N-terminus reaching deep into the receptor's transmembrane core, the same way the native hormones do ^[1].

At the GIP receptor, tirzepatide's N-terminal tyrosine, called Tyr1, points toward two receptor residues, Arg190 and Gln220, and the electron density suggests water-mediated polar interactions among them ^[1]. A second difference matters: tirzepatide has a threonine at position 7, where GIP has isoleucine, and that threonine forms a hydrogen bond with Arg190 ^[1]. The paper reports that tirzepatide's affinity for the GIP receptor equals that of native GIP ^[1].

At the GLP-1 receptor, the same N-terminal tyrosine makes only a weak interaction ^[1]. Molecular dynamics simulations showed a greater tendency for intermittent hydrogen bonding between tirzepatide's fatty acid chain and the GIP receptor than the GLP-1 receptor, consistent with a more compact tirzepatide–GIP receptor complex ^[1]. The authors also report that tirzepatide's affinity at the GLP-1 receptor is about fivefold weaker than GLP-1's, and that it favors cAMP signaling over β-arrestin recruitment, a bias linked to reduced receptor desensitization ^[1].

The fatty acid in question is a C20 fatty diacid attached through a lysine near the middle of tirzepatide's 39-amino-acid chain by a hydrophilic linker ^[1]. That modification lets the peptide bind reversibly to human serum albumin, which helps support once-weekly dosing ^[1]. The study concludes that both the amino acid sequence and the fatty acid modification shape how the molecule behaves at each receptor ^[1].

The paper places the structural work alongside clinical results. A 26-week phase 2b trial showed tirzepatide lowered glucose and body weight in people with type 2 diabetes ^[1]. In the 40-week SURPASS-2 trial, all three tirzepatide doses produced greater glucose and weight reductions than the highest approved dose of semaglutide ^[1]. At the time of publication, the paper describes tirzepatide as an investigational agent ^[1]. Tirzepatide is the active ingredient in Mounjaro and Zepbound.

Why it matters for patients

This study explains a mechanism. It reports no new results in people, and it does not change what any regulator has approved. Nothing in it provides new information about side effects, dosing, or which patients do better on tirzepatide than on a GLP-1 drug such as semaglutide.

The desensitization finding is the part most likely to draw attention. Desensitization is the process by which a receptor becomes less responsive after repeated stimulation. The paper reports less agonist-induced desensitization at the GLP-1 receptor with tirzepatide than with GLP-1 ^[1], and it calls the significance of the cAMP bias “not fully realized” ^[1]. Whether that difference explains tirzepatide's clinical results, or affects how patients feel, has not been established. The paper says the pathway bias “may contribute” to tirzepatide's effects on glucose control and body weight ^[1] — a possibility, not a demonstrated cause.

The experiments were done on purified receptors rather than in patients, so they cannot show how the drug performs in any individual.

What happens next

The paper cites the ongoing phase 3 SURPASS program, with SURPASS-2 already reported ^[1]. It does not describe planned trials or product changes based on these structures, and whether drugmakers will use the findings to design new multi-receptor agonists has not been reported.